Caillot D, Bassaris H, Seifert WF, Van De Velde V, Van Der Geest R, Woestenborghs R, Chwetzoff E, Materman EC, De Beule KL; Interscience Conference on Antimicrobial Agents and Chemotherapy.
Abstr Intersci Conf Antimicrob Agents Chemother Intersci Conf Antimicrob Agents Chemother. 1999 Sep 26-29; 39: 575 (abstract no. 1646).
Univ. Hosp., Dijon
Thirty-one immunocompromized pts with IPA were assigned to receive IV Itr treatment for 2 weeks (days 1 and 2: 200 mg Itr injectable solution twice daily with a 12-hour interval; days 3 to 14: 200 mg Itr once daily), followed by a 12-week oral follow-up period (Itr capsules: 2 x 200 mg/d). The number of responders (complete and partial response) was 15/31 (48%). Adverse events occurring during IV Itr treatment were noted in 28 (90%) pts and during oral Itr treatment in 19 (73%) pts. After 2 days of IV Itr treatment, adequate (>250 ng/ml Itr) plasma concentrations were attained in 91% of the pts. [table: see text].CONCLUSION: the combination of IV Itr followed by oral Itr resulted in adequate plasma concentrations, and appears to be efficacious, safe and convenient therapy for immunocompromized pts with IPA.
Publication Types:
Keywords:
- Aspergillosis, Allergic Bronchopulmonary
- Humans
- Immunocompromised Host
- Influenza, Human
- Itraconazole
- Safety
- immunology
- pharmacokinetics
Other ID:
UI: 102246792
From Meeting Abstracts